Opinions
Bruce Campbell (2)
CareRx
CRRX-T
WATCH
Feb 23, 2022
Interesting business model. Pharmacy services to LTC. Technology automates everything. Continues to add facilities, so revenue and cashflow increasing. Reasonable multiple. Trades thinly, not a lot of institutional volume. Small cap selloff. On his radar.
$4.960
Stock price when the opinion was issued
Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
BUY
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Trades at under 2x sales and growth is positive. The stock is doing well. Debt remains high and they are losing money. Insiders are committed, owning 21% and continue to buy. The acquisition adds $170M to sales. Has held gains this year and is a better mid-cap name in the space. Unlock Premium - Try 5i Free
Healthcare
PAST TOP PICK
(A Top Pick Jun 16/20, Up 34%) One of his biggest positions. Rose during pandemic. Unaffected by lockdowns. Several large, accretive acquisitions, making them the largest player in Canada at 20% of the institutional pharmacy market. Huge tailwinds with the seniors demographic. Focused strategy, well managed, more consolidation to come, plus organic growth.
Healthcare
PAST TOP PICK
(A Top Pick Jun 16/20, Up 37%) One of his biggest positions. Still buying at these levels. Safe way to play healthcare with aging demographics and industry consolidation. Unaffected by the lockdown. Several large, transformative acquisitions. #1 institutional pharmacy player in Canada, with 20% of the market. Launching telemedicine services. Great growth for many years to come.
Healthcare
TOP PICK
Canada's largest pharmacy provider to LTC homes. Winning new business from competitors. Getting into telehealth. Launching pharmacy at your door, for seniors living at home. Demographics behind it. Super well managed. Bargain basement price. Organic and acquisition growth. No dividend. (Analysts’ price target is $8.69)
Healthcare
STRONG BUY
The #1 institutional pharmacy player with 23% market share. Stock did well last year, cheap now. Organic and acquisition growth. Becoming really well managed. Automating fulfillment centres to improve margins. Equity raises caused it to tread water. Solid baseline, should trend up nicely. Demographic tailwind. Getting into medical supply distribution.
Healthcare
STRONG BUY
It was formerly Centric Health which had many businesses and a lot of debt. They paid the debt and sold businesses. Now, they're 100% focussed on Canada's #1 institutional pharmacy which distributes to seniors' homes. They're automating fulfillment centres to expand margins. Again demographics are a tailwind. Tuck-in acquisitions are coming and are integrating some now, so there are expected costs. He holds a large position. Trades at a reasonable valuation. A safe growing stock.
Healthcare
PAST TOP PICK
(A Top Pick Sep 20/21, Down 28%) Canada's largest pharmacy to LTC facilities. Two transformative acquisitions. Over 20% market share. Expects organic and acquisition sales growth and margin improvement. Telehealth. Distributing supplies. Stable, recession-proof, demographic tailwinds, easy valuation.
Healthcare
Advertising